Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
GammaDelta Therapeutics logo — GammaDelta Therapeutics focuses on using γδ T cells to impro...

GammaDelta Therapeutics

GammaDelta Therapeutics focuses on using γδ T cells to improve survival rates of patients with cancer.

Founded 2016 United Kingdom London, United Kingdom 4 employees Seed Biotechnology, Health Care +1

General Information

Company Name GammaDelta Therapeutics
Founded Year 2016
Location United Kingdom London, United Kingdom
Founders / Decision Makers
Team member
Employees 4
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with GammaDelta Therapeutics. To contact GammaDelta Therapeutics, visit gammadeltatx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does GammaDelta Therapeutics compare?

A PDF of GammaDelta Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting GammaDelta Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About GammaDelta Therapeutics

GammaDelta Therapeutics is a UK-based biotechnology startup founded in 2016 by Professor Adrian Hayday and Dr. Oliver Nussbaumer, with support from Cancer Research Technology. The company's mission is to leverage the unique properties of γδ T cells to improve patient outcomes and survival rates in the treatment of haematological malignancies and solid tumors. GammaDelta aims to deliver highly effective allogeneic immunotherapies based on the unique properties of Vδ1+ T cells, with the potential to provide additional benefits towards patient survival. The proprietary isolation and expansion protocols have the ability to selectively generate Vδ1+ T cell populations suitable for clinical application. The company's technologies are based on pioneering research conducted by Professor Adrian Hayday and Dr. Oliver Nussbaumer at King’s College London and the Francis Crick Institute, as well as Professor Bruno Silva-Santos at the University of Lisbon. GammaDelta's innovative approach has garnered recognition for its therapeutic potential, attracting interest from the pharmaceutical industry and investments from Takeda Pharmaceutical Company Limited and Abingworth LLP. The last recorded investment was a Seed Round investment on 16 September 2016, with key investors including Abingworth, King's College London, Cancer Research Technology, and The Francis Crick Institute. With its focus on cutting-edge biotechnology and healthcare, GammaDelta Therapeutics stands at the forefront of advancing innovative immunotherapies for cancer treatment.

Business keywords: immunotherapy, cancer treatment, T-cell therapy, oncology, immunology, cell therapy, academic research, investments, clinical application, allogeneic immunotherapies, solid tumors, hematological malignancies, pharmaceutical industry, tissue resident T cells

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Undisclosed 4
Abingworth King's College London
Abingworth, King's College London +2
16 Sep 2016

GammaDelta Therapeutics Alternatives & Competitors

View All Alternatives
GammaDelta Therapeutics vs
ImmuneBridge
ImmuneBridge United States

Bridging research and translation for a healthy future.

Seed
18 employees
Biotechnology, Health Care
GammaDelta Therapeutics vs
Kiromic Biopharma, Inc.
Kiromic Biopharma, Inc. United States

Cell therapy company with end-to-end bioinformatic, AI targeting, and manufacturing technologies to...

Post-IPO Equity
17 employees
Biopharma, Biotechnology
GammaDelta Therapeutics vs
ONK Therapeutics
ONK Therapeutics Ireland

Pioneering optimally engineered NK cell therapies to cure patients with cancer.

Series A
20 employees
Biotechnology, Health Care
View all alternatives

FAQ About GammaDelta Therapeutics

GammaDelta Therapeutics focuses on using γδ T cells to improve survival rates of patients with cancer.
GammaDelta Therapeutics was founded in 2016.
GammaDelta Therapeutics is headquartered in London, United Kingdom.
GammaDelta Therapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on immunotherapy, cancer treatment, T-cell therapy and oncology.
GammaDelta Therapeutics has approximately 4 employees.
GammaDelta Therapeutics has completed 1 funding round. The latest funding stage is Seed.
Top alternatives and competitors to GammaDelta Therapeutics include ImmuneBridge, Kiromic Biopharma, Inc., ONK Therapeutics, Adaptate Biotherapeutics, Nkarta, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
GammaDelta Therapeutics and ImmuneBridge are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for GammaDelta Therapeutics, https://bouncewatch.com/company/gammadelta-therapeutics, updated 18 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout